Exelixis Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (47)

View All

Latest Posts

About This Stock More About This Stock
This Biotech Looks Good With Increased M&A Activity
Article By: InvestorsAlley
Friday, May 20, 2022 3:49 AM EDT
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.
In this article: ACAD, EXEL, XBI
Read
Early Monday Report - More Moves Out Of China
Article By: Vivian Lewis
Sunday, January 9, 2022 7:24 PM EDT
Before it even turned Monday in the West, China insurers were feeling the heat.
In this article: BIIB, LLY, TSM, ALKS, EXEL, CGEN
Read
Post-Fed Thursday
Article By: Vivian Lewis
Thursday, January 6, 2022 9:00 PM EDT
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
In this article: EXEL, CTRA, ZYME, KL Also: LAZ, LLY, SLB, SAN, PLUG, TEVA, UUUU, ARKK, TAK, GNFT
Read
The Sunday File For Nov. 21
Article By: Vivian Lewis
Sunday, November 21, 2021 7:21 PM EDT
Good news and bad - making up for the short week by getting a Sunday start.
In this article: NIO, JMPLY, EXEL, QCOM
Read
Here's My Top Value Stock To Buy Right Now
Article By: StockNews
Monday, November 1, 2021 8:53 AM EDT
EXEL is working on further expanding cabozantinib’s label. It is currently evaluating the drug as a single agent and in combination with immune checkpoint inhibitors across various indications.
In this article: EXEL Also: BMY, MRK, DSNKY, BGNE, MRTX
Read
All Posts

Latest Tweets for $EXEL

No tweets yet!

PARTNER HEADLINES